These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 3046147)
1. [The use of metamizole as a risk factor in the occurrence of agranulocytosis]. Vlakhov V; Bakracheva N; Popova L Vutr Boles; 1988; 27(2):80-5. PubMed ID: 3046147 [TBL] [Abstract][Full Text] [Related]
2. Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Bäckström M; Hägg S; Mjörndal T; Dahlqvist R Pharmacoepidemiol Drug Saf; 2002; 11(3):239-45. PubMed ID: 12051124 [TBL] [Abstract][Full Text] [Related]
3. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Hedenmalm K; Spigset O Eur J Clin Pharmacol; 2002 Jul; 58(4):265-74. PubMed ID: 12136373 [TBL] [Abstract][Full Text] [Related]
4. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Maj S; Centkowski P Med Sci Monit; 2004 Sep; 10(9):PI93-5. PubMed ID: 15328493 [TBL] [Abstract][Full Text] [Related]
5. [Agranulocytosis and metamizole]. Hoerder U; König HJ; Hartwich G Dtsch Med Wochenschr; 1982 Dec; 107(50):1923-6. PubMed ID: 7140576 [TBL] [Abstract][Full Text] [Related]
7. Metamizole: a 100-year-old grief. Levy M; Shapiro S Ned Tijdschr Geneeskd; 1987 Sep; 131(38):1680-3. PubMed ID: 3670467 [No Abstract] [Full Text] [Related]
8. [Metamizole: an unbearable risk?]. Forth W MMW Munch Med Wochenschr; 1981 Jul; 123(28):1135-7. PubMed ID: 6790946 [No Abstract] [Full Text] [Related]
9. [Metamizole: 100 years of grief]. Offerhaus L Ned Tijdschr Geneeskd; 1987 Mar; 131(12):479-81. PubMed ID: 3574499 [No Abstract] [Full Text] [Related]
10. [Metamizole: a 100-year-old misery]. Ned Tijdschr Geneeskd; 1987 May; 131(20):875-6. PubMed ID: 3587424 [No Abstract] [Full Text] [Related]
12. Agranulocytosis and dipyrone. Vlahov V; Bacracheva N Lancet; 1989 Nov; 2(8673):1215. PubMed ID: 2572920 [No Abstract] [Full Text] [Related]
13. [Benefit-risk considerations in metamizole treatment. Rational recommendations for indications and contra-indications according to current knowledge]. Ell C; Domschke S; Domschke W Fortschr Med; 1982 Apr; 100(14):615-8. PubMed ID: 7084847 [No Abstract] [Full Text] [Related]
14. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Huber M; Andersohn F; Sarganas G; Bronder E; Klimpel A; Thomae M; Konzen C; Kreutz R; Garbe E Eur J Clin Pharmacol; 2015 Feb; 71(2):219-27. PubMed ID: 25378038 [TBL] [Abstract][Full Text] [Related]
17. [Metamizole (dipyrone): mode of action, drug-drug interactions, and risk of agranulocytosis]. Lampl C; Likar R Schmerz; 2014 Dec; 28(6):584-90. PubMed ID: 25199942 [TBL] [Abstract][Full Text] [Related]
18. The incidence of dipyrone-induced agranulocytosis in Greece during 1975. Varonos DD; Santamouris S; Karambali S J Int Med Res; 1979; 7(6):564-8. PubMed ID: 520659 [TBL] [Abstract][Full Text] [Related]
19. The incidence of metamizole sodium-induced agranulocytosis in Poland. Maj S; Lis Y J Int Med Res; 2002; 30(5):488-95. PubMed ID: 12449518 [TBL] [Abstract][Full Text] [Related]
20. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Stammschulte T; Ludwig WD; Mühlbauer B; Bronder E; Gundert-Remy U Eur J Clin Pharmacol; 2015 Sep; 71(9):1129-38. PubMed ID: 26169297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]